cagkansayin
Sangamo Therapeutics (NASDAQ:SGMO) lost nearly half of its market cap in early trading on Tuesday after Pfizer (NYSE:PFE) decided to end a collaboration with the company for its gene therapy giroctocogene fitelparvovec targeted at the bleeding disorder hemophilia A.
Sangamo’s (